Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Recommendation of "Moderate Buy" by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.56.

Several equities research analysts have recently weighed in on ATEC shares. Needham & Company LLC boosted their target price on shares of Alphatec from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Barclays boosted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th.

Alphatec Stock Down 0.9 %

Alphatec stock traded down $0.10 during midday trading on Monday, hitting $10.86. 1,109,947 shares of the stock were exchanged, compared to its average volume of 1,617,464. Alphatec has a 1 year low of $4.88 and a 1 year high of $15.69. The firm has a market cap of $1.54 billion, a P/E ratio of -8.48 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a 50 day moving average price of $10.44 and a two-hundred day moving average price of $8.19.

Insider Activity

In other news, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the transaction, the chief operating officer now directly owns 867,677 shares of the company's stock, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares of the company's stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 222,376 shares of company stock valued at $2,557,148. Company insiders own 22.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank boosted its stake in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the period. R Squared Ltd acquired a new position in Alphatec during the 4th quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its stake in Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after purchasing an additional 4,234 shares during the period. Quarry LP boosted its stake in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares during the period. Finally, Newton One Investments LLC acquired a new stake in shares of Alphatec in the 4th quarter worth approximately $50,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.